Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis
- PMID: 9688061
- DOI: 10.1023/a:1011986312541
Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis
Abstract
Purpose: Nitric oxide synthase (NOS) inhibitors such as Nitro-L-arginine (L-NA) are being considered for the management of hypotension observed in septic shock. However, little information is available regarding the pharmacokinetic and pharmacodynamic properties of these agents. Our objective was to examine the relationships between L-NA plasma concentration and various hemodynamic effects such as cardiac index (CI), mean arterial pressure (MAP), and heart rate (HR) elicited by L-NA administration in rats.
Methods: L-NA was infused at doses between 2.5-20 mg/kg/hr in anesthetized rats over one hour. Hemodynamic effects and plasma L-NA levels were determined.
Results: Infusion of L-NA resulted in dose-dependent increases in MAP and systemic vascular resistance (SVR), decreases in CI, and minimal change in HR. The relationships between the hemodynamic effects and plasma L-NA levels were not monotonic, and hysteresis was observed. Using nonparametric analysis, the equilibration half-time (t1/2,keo) between plasma L-NA and the hypothetical effect site was determined to be 51.5 +/- 6.6 min, 42.4 +/- 10.1 min, 43.4 +/- 9.0 min for MAP, CI, and SVR, respectively (n = 14). The Emax and EC50 values obtained were + 32.5 +/- 8.4 and 2.6 +/- 1.3 microg/ml for MAP and -52.9 +/- 15.6 and 3.7 +/- 1.8 microg/ml for CI, respectively.
Conclusions: Although L-NA can bring about beneficial elevation of MAP, such effect is always accompanied by a stronger effect on CI depression. Dose escalation of L-NA may bring about detrimental negative inotropic effect and loss of therapeutic efficacy.
Similar articles
-
Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans.Br J Clin Pharmacol. 1999 May;47(5):539-44. doi: 10.1046/j.1365-2125.1999.00930.x. Br J Clin Pharmacol. 1999. PMID: 10336578 Free PMC article. Clinical Trial.
-
Endotoxin alters the systemic disposition of nitric oxide synthase inhibitors in the awake sheep.Clin Exp Pharmacol Physiol. 1997 Jun;24(6):391-7. doi: 10.1111/j.1440-1681.1997.tb01207.x. Clin Exp Pharmacol Physiol. 1997. PMID: 9171941
-
Selective versus non-selective suppression of nitric oxide synthase on regional hemodynamics in rats with or without LPS-induced endotoxemia.Naunyn Schmiedebergs Arch Pharmacol. 2003 Apr;367(4):372-9. doi: 10.1007/s00210-002-0684-1. Epub 2003 Mar 4. Naunyn Schmiedebergs Arch Pharmacol. 2003. PMID: 12690429
-
Dissociation between the increase in systemic vascular resistance induced by acute nitric oxide synthesis inhibition and the decrease in cardiac output in anesthetized dogs.J Cardiovasc Pharmacol. 1997 Jan;29(1):45-8. doi: 10.1097/00005344-199701000-00007. J Cardiovasc Pharmacol. 1997. PMID: 9007669
-
Effects of N omega-nitro-L-arginine and N-acetyl-L-cysteine on the reversal of one-kidney, one-clip hypertension.Am J Hypertens. 1997 Nov;10(11):1208-15. doi: 10.1016/s0895-7061(97)00223-9. Am J Hypertens. 1997. PMID: 9397238
Cited by
-
Pharmacokinetics and pharmacodynamics of 7-nitroindazole, a selective nitric oxide synthase inhibitor, in the rat hippocampus.Pharm Res. 2001 Nov;18(11):1607-12. doi: 10.1023/a:1013042817281. Pharm Res. 2001. PMID: 11758770
-
Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.AAPS J. 2010 Dec;12(4):592-601. doi: 10.1208/s12248-010-9220-2. Epub 2010 Jul 24. AAPS J. 2010. PMID: 20652780 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources